Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic options

<p><strong>Foundation:</strong> neoplastic diseases in general and particularly those of the central nervous system constitute health problems that negatively impact personal, family and society life. Therefore, the search for new therapeutic modalities that produce an impact on su...

Full description

Saved in:
Bibliographic Details
Main Authors: María Margarita Ríos Cabrera, Iraldo Bello Rivero, Javier Cruz Rodríguez
Format: Article
Language:Spanish
Published: Centro Provincial de Información de Ciencias Médicas. Cienfuegos 2024-07-01
Series:Medisur
Subjects:
Online Access:http://medisur.sld.cu/index.php/medisur/article/view/45207
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832576830660411392
author María Margarita Ríos Cabrera
Iraldo Bello Rivero
Javier Cruz Rodríguez
author_facet María Margarita Ríos Cabrera
Iraldo Bello Rivero
Javier Cruz Rodríguez
author_sort María Margarita Ríos Cabrera
collection DOAJ
description <p><strong>Foundation:</strong> neoplastic diseases in general and particularly those of the central nervous system constitute health problems that negatively impact personal, family and society life. Therefore, the search for new therapeutic modalities that produce an impact on survival and economic feasibility in their use is very important.<br /><strong>Objective:</strong> to demonstrate the economic feasibility of the interferons (Heberferón®) combination compared to other products approved or under study in the national and foreign contexts in the patients treatment with high-grade brain tumors without therapeutic options.<br /><strong>Methods:</strong> a cost-effectiveness economic evaluation was developed in a 40 patients sample (23 treated with Heberferón® and 17 with Nimotuzumab) treated at the Arnaldo Milián Castro Santa Clara Provincial Hospital. The effectiveness parameter for each of the comparators was obtained by doing a systematic search in Medline (Pubmed) and Cochrane.<br /><strong>Results:</strong> Heberferón® was less expensive for each month of life saved in relation to the rest of the medications.<br /><strong>Conclusions:</strong> the economic feasibility of using Heberferón® was evident, when comparing it with other products to treat patients with highly malignant brain tumors without therapeutic options.</p>
format Article
id doaj-art-60f72d29172940eeacd73a33e0a4a871
institution Kabale University
issn 1727-897X
language Spanish
publishDate 2024-07-01
publisher Centro Provincial de Información de Ciencias Médicas. Cienfuegos
record_format Article
series Medisur
spelling doaj-art-60f72d29172940eeacd73a33e0a4a8712025-01-30T21:29:03ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2024-07-012246726782530Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic optionsMaría Margarita Ríos Cabrera0Iraldo Bello Rivero1Javier Cruz Rodríguez2Hospital Provincial Clínico-Quirúrgico Arnaldo Milián Castro. Santa Clara. Cuba.Centro de Ingeniería Genética y Biotecnología. La Habana. Cuba.Hospital Provincial Clínico-Quirúrgico Arnaldo Milián Castro. Santa Clara. Cuba.<p><strong>Foundation:</strong> neoplastic diseases in general and particularly those of the central nervous system constitute health problems that negatively impact personal, family and society life. Therefore, the search for new therapeutic modalities that produce an impact on survival and economic feasibility in their use is very important.<br /><strong>Objective:</strong> to demonstrate the economic feasibility of the interferons (Heberferón®) combination compared to other products approved or under study in the national and foreign contexts in the patients treatment with high-grade brain tumors without therapeutic options.<br /><strong>Methods:</strong> a cost-effectiveness economic evaluation was developed in a 40 patients sample (23 treated with Heberferón® and 17 with Nimotuzumab) treated at the Arnaldo Milián Castro Santa Clara Provincial Hospital. The effectiveness parameter for each of the comparators was obtained by doing a systematic search in Medline (Pubmed) and Cochrane.<br /><strong>Results:</strong> Heberferón® was less expensive for each month of life saved in relation to the rest of the medications.<br /><strong>Conclusions:</strong> the economic feasibility of using Heberferón® was evident, when comparing it with other products to treat patients with highly malignant brain tumors without therapeutic options.</p>http://medisur.sld.cu/index.php/medisur/article/view/45207neoplasias encefálicasinterferonesprotocolos clínicos
spellingShingle María Margarita Ríos Cabrera
Iraldo Bello Rivero
Javier Cruz Rodríguez
Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic options
Medisur
neoplasias encefálicas
interferones
protocolos clínicos
title Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic options
title_full Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic options
title_fullStr Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic options
title_full_unstemmed Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic options
title_short Heberferón®’s economic feasibility in patients with high-grade brain tumors without therapeutic options
title_sort heberferon r s economic feasibility in patients with high grade brain tumors without therapeutic options
topic neoplasias encefálicas
interferones
protocolos clínicos
url http://medisur.sld.cu/index.php/medisur/article/view/45207
work_keys_str_mv AT mariamargaritarioscabrera heberferonseconomicfeasibilityinpatientswithhighgradebraintumorswithouttherapeuticoptions
AT iraldobellorivero heberferonseconomicfeasibilityinpatientswithhighgradebraintumorswithouttherapeuticoptions
AT javiercruzrodriguez heberferonseconomicfeasibilityinpatientswithhighgradebraintumorswithouttherapeuticoptions